Abstract |
Starting in 1988, 72 patients with advanced human immunodeficiency virus ( HIV) infection were enrolled in a phase I study of didanosine at the National Cancer Institute. Beginning in 1992, patients with decreases in CD4 cell counts could switch to a combination of zidovudine and didanosine. The estimated median survival for all patients was 28 months (95% confidence interval, 23-46). However, for patients whose entry CD4 cell counts were 100-300/mm3, the estimated 4-year survival was 80%. Baseline CD4 and CD8 cell counts, hemoglobin, lymphocytes, sedimentation rates, diagnosis of AIDS, and fever were significant predictors of overall survival. Principal toxicities were pancreatitis and peripheral neuropathy; no new toxicities were seen with extended didanosine treatment that had not been observed in shorter-term studies. This 5-year follow-up shows that didanosine can be tolerated for > 4 years in some patients with advanced HIV infection and may have particular long-term utility in patients with moderately advanced immunosuppression.
|
Authors | B Y Nguyen, R Yarchoan, K M Wyvill, D J Venzon, J M Pluda, H Mitsuya, S Broder |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 171
Issue 5
Pg. 1180-9
(May 1995)
ISSN: 0022-1899 [Print] United States |
PMID | 7751692
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- CD4 Lymphocyte Count
- Didanosine
(administration & dosage, adverse effects, therapeutic use)
- Disease Progression
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- HIV Infections
(drug therapy, immunology, mortality)
- Humans
- Male
- Middle Aged
- Survival Rate
- Zidovudine
(therapeutic use)
|